BACKGROUND: Accurate prognostication is essential to the optimal management of laryngeal cancer. Predictive models have been developed to calculate the risk of oncologic outcomes, but extensive external validation of accuracy and reliability is necessary before implementing them into clinical practice. METHOD: Four published prognostic calculators that predict 5-year overall survival for patients with laryngeal cancer were evaluated using patient information from a prospective epidemiology study cohort (n 5 246; median follow-up, 60 months) with previously untreated, stage I through IVb laryngeal squamous cell carcinoma. RESULTS: Different calculators yielded substantially different predictions for individual patients. The observed 5-year overall survival was significantly higher than the averaged predicted 5-year overall survival of the 4 calculators (71.9%; 95% confidence interval [CI], 65%-78%] vs 47.7%). Statistical analyses demonstrated the calculators' limited capacity to discriminate outcomes for risk-stratified patients. The area under the receiver operating characteristic curve ranged from 0.68 to 0.72. C-index values were similar for each of the 4 models (range, 0.66-0.68). There was a lower than expected hazard of death for patients who received induction (bioselective) chemotherapy (hazard ratio, 0.46; 95% CI, 0.24-0.88; P 5.024) or primary surgical intervention (hazard ratio, 0.43; 95 % CI, 0.21-0.90; P 5.024) compared with those who received concurrent chemoradiation. CONCLUSIONS: Suboptimal reliability and accuracy limit the integration of existing individualized prediction tools into routine clinical decision making. The calculators predicted significantly worse than observed survival among patients who received induction chemotherapy and primary surgery, suggesting a need for updated consideration of modern treatment modalities. Further development of individualized prognostic calculators may improve risk prediction, treatment planning, and counseling for patients with laryngeal cancer. Cancer 2018;124:706-16. V C 2017 American Cancer Society.
INTRODUCTION
The multidisciplinary management of head and neck cancer (HNC) depends critically on accurate risk stratification and prediction of clinical outcomes. 1 Managing laryngeal cancer introduces additional challenges secondary to debilitating functional impairments that often accompany the primary disease and/or related therapeutic interventions. [2] [3] [4] [5] Accepted standards for tumor staging and oncologic prognostication continue to be helpful in confronting these challenges and guiding decision making. 6, 7 However, in order to further individualize treatment selections that enhance survival and minimize morbidity, more sophisticated methods that successfully capitalize on emerging discoveries related to tumor biology/genomics and patient factors are mandatory. 8, 9 Treatment decision making is particularly complex for laryngeal cancer because of the various treatment options available and the differing short-term and long-term functional consequences that affect quality of life and survival. The management of laryngeal cancer has experienced substantial evolution, primarily driven by the implementation of chemotherapeutic modalities and novel organ-preservation strategies. 3, [10] [11] [12] This further emphasizes the need for modernized tools when calculating prognostic estimates.
The heterogeneity of laryngeal cancer is 1 of the many factors that impose formidable challenges to the accurate prediction of individual survival. 13 Survival is influenced by numerous variables, including multiple and diverse tumor-specific (size, grade, genomics, biologic features, and stage) and patient-related (age, race, sex, immune status, smoking status, and medical comorbidities) factors. 14 The TNM (tumor-lymph node-metastasis) staging system defined by the American Joint Committee on Cancer (AJCC) is the current prognostic standard for HNC and predicts survival with reasonable accuracy. 15 Despite its trusted reputation and ubiquitous assimilation in clinical practice, TNM staging fails to incorporate many criteria that demonstrate prognostic value, thereby limiting its ability to tailor risk predictions to an individual patient. 15 Studies suggest that implementing additional tumor, patient, and treatment characteristics into risk calculations can promote superior prognostic accuracy across a diverse range of oncologic subspecialties. [16] [17] [18] [19] The current trend in attitudes toward electronic health information suggests that online versions of these calculators would be readily implemented into medical decision making. [20] [21] [22] [23] [24] As a means of regulating newly published risk predictors, the AJCC recently published 16 inclusion and exclusion criteria that are required for endorsement of any probability or risk model. 25 These benchmarks should help to ensure that performance metrics, compatibility, and clinical relevance are robust amid the expansion of new prediction tools. 25 Investigators have worked to address the dearth of individualized clinical decision tools currently available to interdisciplinary teams that manage head and neck squamous cell carcinoma (HNSCC) by developing prognostic calculators specific to HNCs. [26] [27] [28] Risk calculators wield potential clinical value but have not yet been subjected to sufficient evaluation and validation to warrant their assimilation into routine practice. Moreover, many of these were generated with older data, which may not be directly relevant to current patients. To assess clinical prognostic tools, analyses that compare the calculators' predictions with each other and with modern observed outcomes are imperative. 29 These validation studies are best performed on independent patient cohorts that encompass diverse geographic regions and patient demographics. 30, 31 The objective of the current study was to use an independent patient cohort to externally evaluate and validate published prognostic calculators designed for patients with laryngeal cancer.
MATERIALS AND METHODS
The University of Michigan Institutional Review Board evaluated and approved this study. All participants provided written informed consent at enrollment in this prospective epidemiology study (typically at the time of diagnosis).
Prognostic Calculators
Prognostic clinical decision tools were identified using online search engines and expert input. PubMed and Google Scholar were investigated for peer-reviewed publications using a combination of search terms representing disease (larynx, cancer), prognosis (ie, survival, risk, prediction, and outcome) and methodology (calculator, tool, model, and nomogram). Multidisciplinary HNC specialists were also surveyed to probe for existing or emerging prognostic tools not identified in the online search. 16 Potential calculator candidates were evaluated for eligibility. Inclusion criteria mandated that the calculator used clinical data to predict 5-year overall survival for squamous cell carcinoma of the larynx. Four prognostic calculators were identified (MAASTRO, LifeMath, Leiden, and MyCancerJourney), and each model was reviewed for content and format. [26] [27] [28] The calculators' mathematical formulas were acquired from the original publication, supplementary online materials, or computational derivation. We note that the MyCancerJourney calculator does not have an associated peerreviewed publication. Table 1 26-28 summarizes each calculator and includes the period, sample size, and other characteristics that describe the original study cohorts. Each calculator functions according to an equation constructed to represent the relation between tumor characteristics, patient demographics, treatment modalities received, and observed survival outcomes. The calculators considered a distinct set of variables in their prognostic equation and assigned differing quantities of statistical weight to these variables ( Table 2 and Supporting Tables 1-7 ; see online supporting information). The calculators were modeled from patient data contained in the Surveillance, Epidemiology, and End Results (SEER) registry; regional study cohorts; or a combination of 2 patient populations. The 4 study cohorts included patients who received treatment with curative intent between 1973 and 2009.
26-28

Patients
The analysis data set was derived from a single-institution, prospectively maintained HNC epidemiologic study. [32] [33] [34] [35] In total, 246 patients with biopsy-proven, previously untreated, AJCC stage I through IVb squamous cell carcinoma of the larynx who were diagnosed and treated with curative intent at the University of Michigan Health System between 2003 and 2014 were included. (32 patients; 20 .1%), received a single cycle of induction chemotherapy (bioselective) followed by either combined chemoradiation for a tumor response >50% or total laryngectomy for a tumor response <50% (70 patients; 46.1%), or received definitive chemoradiation (50 patients; 32.9%). The median follow-up was 60 months. Tumor-specific, patient-specific, and treatmentspecific variables were exported from the database and confirmed by chart abstraction.
The calculators were designed for utility before oncologic treatment. Consequently, pretreatment clinical information was used to populate the relevant variables. Pathologic information was only used as a substitute when clinical information was not available. Missing variables were populated using established algorithms, as described in the online supporting information. Exclusion criteria included carcinoma in situ, distant metastasis at the time of diagnosis, and synchronous primary tumors, not including basal or squamous cell carcinoma of the skin.
Statistical Analysis
Each calculator was used to individually predict 5-year overall survival for 246 patients in our independent external validation cohort. The arithmetic average of the predictions from the 4 calculators was tested as a distinct (fifth) calculator, which is referred to as the "mean" in subsequent analyses. The agreement between these predictions was compared using scatterplots, Spearman correlation coefficients, and the proportion of 5-year overall survival predictions that differed by <0.10 between separate calculators. The calibration of each calculator was assessed using Kaplan-Meier plots, which stratified patients into equal-sized quintiles according to calculatorpredicted risk. The average predicted risk for each quintile was compared with the estimated 5-year survival for that quintile in a calibration plot. The discriminatory ability of each calculator was assessed using both the area under the receiver operating characteristic (ROC) curve for the binary outcome of survival at 5 years 36 and the C-index. Both the C-index and the 5-year area under the ROC curve (AUC) measure the concordance between the predicted risk and the survival outcome and are frequently reported in the literature.
To assess which factors may be responsible for discrepancies between the predicted outcomes and observed survival, a separate Cox model was fit for each possible factor and adjusted for the predicted risk as measured by the mean prediction. All tests for statistical significance used 95% confidence intervals (CIs) and were 2-sided. For treatment factors, a calibration plot was used to elucidate which treatment modalities were not well calibrated with the predicted risk. The method used to construct the calibration plot is described in the online supporting information.
RESULTS
The patient cohort represented the typical distribution and epidemiology of patients with laryngeal cancer. Most patients were Caucasian, current/former smokers, and men with no or mild medical comorbidities. Slightly less than one-half had a glottic subsite, whereas the majority of tumors originated in the supraglottic larynx. The observed 5-year overall survival was 71.9% (95% CI, 65%-78%), whereas each calculator predicted significantly worse outcomes and contributed to a mean predicted 5-year overall survival of 47.7%. Figure 1 describes each calculator's predicted 5-year survival for our patient population. Visual assessment of the estimates suggests that MAASTRO and MyCancerJourney have a tendency to predict worse outcomes; both have more predictions clustered at lower values than the other calculators. MAASTRO exhibits the greatest discrepancy in its prognostication for patients with high-risk disease. MyCancerJourney has more variation in its predictions. Comparisons of MyCancerJourney and MAASTRO with the remaining 2 calculators demonstrated less agreement and were characterized by lower correlation coefficients.
The Leiden and LifeMath calculators demonstrated the closest correlation coefficient (q 5 0.816), and the weakest association occurred between LifeMath and MyCancerJourney (q 5 0.644). Supporting Table 8 (see online supporting information) reports the percentage of patients for which a selected pair of calculators predicted 5-year overall survival within 0.10. For example, if 1 calculator predicted a 50% 5-year overall survival for a given patient, then the paired calculator was considered to be in consensus if it predicted between 40% and 60% 5-year overall survival for the same patient. Prognostic consensus 
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Cancer February 15, 2018 between calculators was variable, and survival estimates typically agreed within 0.10 for < 50% of the cohort. Figure 2a displays Kaplan-Meier survival plots that used calculator predictions to risk-stratify the patients into equal-portioned quintiles. The 4 calculators were reasonably effective in discriminating between these risk quintiles, but LifeMath and Leiden were less adroit in stratifying low-risk and high risk-patients, whereas MyCancerJourney and MAASTRO were less able to discriminate middle-tiered risk. The mean of the calculators more accurately stratified risk for each of the quintiles. Calibration studies are summarized in Figure 3a and demonstrate lower survival estimates in relation to observed outcomes for each risk-stratified quintile. MAAS-TRO was especially pessimistic for high-risk patients, and LifeMath was well calibrated to observed outcomes for patients with middle-tiered risk.
Cox modeling identified male sex (hazard ratio [HR], 2.03; 95% CI, 1.00-4.11; P 5 .031) and initial planned treatment as additional factors that added predictive value, even after adjusting for the predicted risk from the calculators. Laryngeal subsite (glottis vs supraglottic) was not significantly related to survival after adjusting for calculator predictions (Supporting Table 9 ; see online supporting information). Figure 3b demonstrates that there was a lower than expected hazard of death for those patients in the cohort who received induction (bioselective) chemotherapy (HR, 0.46; 95% CI, 0.24-0.88; P 5 .024) or underwent primary surgical intervention (HR, 0.43; 95% CI, 0.21-0.90; P 5 .024) compared with those who received primary chemoradiation. Adjusted HRs for all other factors are listed in Supporting Table 9 (see online supporting information).
DISCUSSION
Available prognostic calculators generated variable predictions with inconsistent accuracy compared with observed outcomes in an external, prospectively maintained cohort of patients with laryngeal cancer. The 4 calculators were designed with various degrees of similarity, but substantial disparity in performance was evident. We have reported both the discriminatory ability and the calibration properties of the calculators, and these can be thought of as measures of the accuracy of the relative and absolute predictions, respectively. Relative predictions indicate whether the patients can be correctly ranked according to risk, and absolute predictions indicate whether the predicted probabilities of survival are correct. Both types of predictions are important, and both were deficient for each of the 4 calculators.
Differences in patient cohorts, prognostic variables, statistical modeling, and inherent calculator limitations contributed to this deficiency and highlight many of the challenges associated with oncologic prognostication. LifeMath and MyCancerJourney both used the SEER population as their study cohort but exhibited the weakest association in risk prediction. This observation emphasizes the importance of incorporating and weighing prognostic variables accurately. 37 Comorbidity status has proven to be useful in predicting outcomes but was only integrated into the Leiden and MyCancerJourney calculators, providing further explanation for observed differences in calculator performance. 38 The AJCC established guidelines in 2016 that work to synchronize the development of future prognostic calculators, but meaningful discrepancies in the perceived importance of prognostic variables will likely persist. 25 The MAASTRO calculator was developed in the Netherlands using a study cohort of 994 patients with laryngeal cancer between 1977 and 2008. 27 This calculator was designed for patients who only received radiation therapy as their primary treatment modality, and exclusion criteria included carcinoma in situ, distant metastases, and chemotherapy. MAASTRO's internal validation demonstrated an AUC of 0.73, whereas traditional TNM staging demonstrated an AUC of 0.62 for the study cohort. 27 Previous external validations yielded AUC values of 0.68, 0.74, 0.76, and 0.71. Compared with survival predictions for our entire external cohort, predictions for the 55 patients who exclusively received radiation demonstrated similar calibration, better correlation to predictions from the other calculators, and substantially improved AUC and C-index values (Supporting Table 10 and Supporting Figs. 1, 2, and 3; see online supporting information). Our study produced the first nonEuropean external validation with an AUC of 0.72 when applied to all 246 patients and an AUC of 0.81 when applied to just those 55 patients who received radiation only. This calculator's pessimistic tendency could be explained by the evolving role of multimodality therapy, although the absolute incremental overall survival benefit of chemotherapy over radiation alone in laryngeal cancer is fairly modest (5%) outside of bioselection. 39 The calculator also has a noticeable, unfavorable HR for male sex and low hemoglobin count; however, many patients in our cohort were anemic but had better-than-predicted outcomes. In summary, the calculator's performance was fair considering the fundamental differences in the study cohort from which it was developed.
The LifeMath calculator was developed using 50,145 American patients with all sites of HNC in the SEER database between 1980 and 2009. 26 Internal validation and external validation on 1362 patients from Massachusetts General Hospital were performed using an incomparable correlation metric. The current study provides an external validation with a C-index of 0.68 and an AUC of 0.71. The accuracy of this calculator may have been limited by its neglect of comorbidity status, a variable that is not available in the SEER database. The Leiden calculator was developed using a study cohort of 1371 Dutch patients with several different sites of HNC between 1981 and 1998. 28 Internal validation demonstrated a C-index of 0.73, whereas an external validation on 598 patients from the Siteman Cancer Center yielded a C-index of 0.69. The current study provides an additional external validation with a C-index of 0.66. The model likely produced pessimistic survival estimates secondary to continued evolution and refinement of treatment over the past 4 decades.
MyCancerJourney used SEER data between 1973 and 1996 and Barnes-Jewish Hospital data between 1995 and 2001 to construct its model, but it did not have a publication to accompany its online calculator. The calculator performed with a C-index of 0.66 and an AUC of 0.70 in the current study. MyCancerJourney used a novel comorbidity metric to characterize patients. The majority of variations in outcome predictions could be explained by the grouping of patients according to treatment modality and other parameters, which resulted in substantial prognostic fluctuation.
Each of the calculators was designed using a training data set that included patients from over 35 years ago. Consequently, many of the patients in the study cohort did not receive treatment according to modern strategies. Reliance on older patient data likely contributed to the accumulative tendency to estimate worse than observed survival in the study cohort and underscores the importance of ensuring reliability and accuracy before adopting these into clinical practice.
In contrast to a previous study of currently available oral cavity cancer calculators, the patients with laryngeal cancer in our cohort demonstrated consistently better survival compared with the calculators' predicted outcomes. 30 This observation reinforces the hypothesis that individualized treatment paradigms for laryngeal cancer need to be considered when predicting survival. Whether this represents differences among the patients themselves or the individualized treatment approaches used remains speculative. However, both induction chemotherapy (bioselective) for subsequent treatment selection and/or primary surgical intervention were associated with survival benefits that were greater than expected after adjustments for calculator-estimated survival. Individualized treatment paradigms that integrate neoadjuvant bioselection are associated with a significant survival benefit and may account for the superior outcomes observed. 35 These findings reinforce the need for updated survival calculators and provide further evidence that oncologic interventions and institution-specific care are independent variables that affect the prognosis of patients with laryngeal cancer.
The absence of laryngeal cancer clinical practice guidelines that clearly specify preferred treatment modality may be contributing to disparities in calculator performance. Established practice guidelines help to optimize patient outcomes and help to standardize the value of care. [40] [41] [42] However, emerging evidence suggests that adherence to current guidelines established by the American Head and Neck Society and the National Comprehensive Cancer Network does not significantly improve outcomes. 43 Therapeutic regimens are complicated by the range of available treatment modalities and the need to individualize these based on patient, tumor, and institutional factors, making population-level recommendations challenging. 44 There is a growing impetus for evaluating the value of cancer care. Judging value involves the balanced consideration of quality and outcome delivered and remains especially difficult to measure in oncology because of its multidisciplinary nature, need for prolonged follow-up, and consideration of post-treatment function as well as survival. 45 To address these challenges, prognostic calculators could be modeled from patient cohorts that received treatment according to optimized quality metrics. Once appropriately accurate, precise, and calibrated, such calculators could help to establish standardized expected outcomes for individually risk-stratified patients. Comparing an institution's outcomes with calculator predictions on an individualized and risk-stratified basis may serve as an effective method for evaluating and comparing relative quality and value. 45, 46 There are inherent limitations to this study, chiefly involving the single-institutional data, which may not reflect practice patterns or outcomes in other populations. The patients in our cohort also were treated by an experienced multidisciplinary team and had comprehensive follow-up, allowing appropriate salvage treatment for recurrence when necessary. Additional limitations may be linked to the improved outcomes generally associated with treatment in academic centers. 35, 40, 42, [47] [48] [49] The accuracy of the SEER data, as well as the calculators relying on it, may be confounded if incurable patients treated for palliation were included or other inaccuracies in treatment Original Article details were present. Missing variables were an additional source of error in this evaluation. However, derived values (for missing variable methods, see online supporting information) for hemoglobin, radiation dosage, and greatest tumor dimension rarely led to substantial differences in survival predictions, helping to mitigate this concern. The calculators do not consider the role of human papillomavirus, and the incidence and prognostic impact of human papillomavirus in laryngeal cancer is considerably lower than that in oropharyngeal cancer. 50 There is a need for more accurate prognostic calculators that can predict individualized outcomes for patients with laryngeal cancer. Currently available prognostic calculators vary in their ability to consistently and accurately predict survival in an external cohort of patients with laryngeal cancer. Suboptimal reliability and accuracy limit the potential integration of existing individualized prediction tools into routine clinical practice. The calculators estimated significantly worse than observed survival among patients who received induction bioselective chemotherapy and underwent primary surgery, suggesting that modern treatment modalities must be better integrated into revised prediction tools. Deficiencies in calculator performance may be further explained by institutional variation in oncologic outcomes. Potential avenues to improve the performance of calculators include using contemporary patient cohorts, integrating biomarkers, and harnessing the promise of the genomic frontier as these data emerge. The use of statistical and machine-learning approaches when data sets are large is another intriguing possibility to create mechanisms that can more nimbly respond to exponentially complex and evolving data. 51 These data raise questions about the inherent value of oncologic nomograms. We contend that they are useful for patients to estimate individualized prognosis and perhaps for comparing results across different cohorts. Predictive models that guide treatment selection might be of higher value and could witness increasing demand as the arsenal of available therapies continues to proliferate and individualize. Improved individualized calculators may help to assign value of oncologic care and will be critical in refining the ability of multidisciplinary teams to predict risk, plan shared treatment-related decision making, and counsel patients effectively. 
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